DelveInsight’s, “Tetanus Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Tetanus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Tetanus Pipeline Report
- DelveInsight’s Tetanus Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Tetanus treatment.
- The leading Tetanus Companies includes Boryung Biopharma, Zydus Healthcare, G C Pharma, KM Biologics, Trinomab Biotech, Zydus Lifesciences, Changchun BCHT Biotechnology, and others
- The promising Tetanus Therapies in the pipeline includes Adacel, REPEVAX, Acellular pertussis vaccine, and others.
- The companies and academics are working to assess challenges and seek opportunities that could influence Tetanus R&D. The therapies under development are focused on novel approaches to treat/improve Tetanus.
Get an overview of the Tetanus Pipeline landscape @ Tetanus Emerging Therapies
Tetanus Overview
Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person. The bacteria are usually found in soil, dust, and manure and enter the body through breaks in the skin — usually cuts or puncture wounds caused by contaminated objects. Tetanus is uncommon in the United States, with an average of about 30 reported cases each year. Nearly all cases of tetanus are among people who did not get all the recommended tetanus vaccinations. This includes people who have never received a tetanus vaccine and adults who don’t stay up to date on their 10-year booster shots. Tetanus is an infection caused by a bacterium called Clostridium tetani. Spores of tetanus bacteria are everywhere in the environment, including soil, dust, and manure. The spores develop into bacteria when they enter the body.
Latest Breakthroughs and Developments in the Tetanus Treatment Landscape
- GC Pharma lead candidate GC 3111A is being developed for the treatment of Tetanus.GC3111A, belongs to the class of bacterial vaccines.It works as immunostimulants.GC 3111A is still in phase II trials for Diphtheria, Pertussis and Tetanus (Prevention) in South Africa.
- BR TD 1001 is a lead candidate of Boryung Biopharma, which is being developed for the treatment of tetanus.BR TD 1001, was being investigated in Phase 3 study to evaluate immunogenicity by measuring the seroprotection rate against diphtheria and tetanus at 28 days after vaccination with BR-TD-1001 and Td-pur-inj.
- TNM002 (human monoclonal antibody against tetanus toxin) is being developed for the treatment of Tetanus. TNM 002, works as Bacterial toxin inhibitors. It is Phase I stage of development for the treatment of Tetanus.
Tetanus Emerging Drugs
- GC 3111A : GC Pharma
- BR TD 1001 : Boryung Biopharma
- TNM 002 : Trinomab Biotech
Get to know more information about Tetanus treatment therapies @ Tetanus Clinical Trials
Tetanus Pipeline Therapeutics Analysis
There are approx. 20+ key companies which are developing the therapies for Tetanus. The companies which have their Tetanus drug candidates in the most advanced stage, i.e. phase III include, Boryung Biopharma.
DelveInsight’s Tetanus Pipeline Report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Discover more about therapy set to grab substantial Tetanus Pipeline landscape @ Tetanus Pipeline Therapeutics Assessment
Scope of the Tetanus Pipeline Report
- Coverage- Global
- Tetanus Pipeline Companies- Boryung Biopharma, Zydus Healthcare, G C Pharma, KM Biologics, Trinomab Biotech, Zydus Lifesciences, Changchun BCHT Biotechnology, and others
- Tetanus Pipeline Therapies- Adacel, REPEVAX, Acellular pertussis vaccine, and others
- Tetanus Pipeline Assessment by Product Type
- Tetanus Pipeline Assessment by Stage and Product Type
- Tetanus Pipeline Assessment by Route of Administration
- Tetanus Pipeline Assessment by Stage and Route of Administration
- Tetanus Pipeline Assessment by Molecule Type
- Tetanus Pipeline Assessment by Stage and Molecule Type
Table of Content
- Introduction
- Executive Summary
- Tetanus: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Tetanus– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- BR TD 1001 : Boryung Biopharma
- Last Stage Products (Phase III)
- Drug Name: Company Name
- Mid Stage Products (Phase II)
- GC 3111A: GC Pharma
- Preclinical and Discovery Stage Products
- Drug name: Company Name
- Inactive Products
- Tetanus Key Companies
- Tetanus Key Products
- Tetanus – Unmet Needs
- Tetanus – Market Drivers and Barriers
- Tetanus – Future Perspectives and Conclusion
- Tetanus Analyst Views
- Tetanus Key Companies
- Appendix
Got Queries? Reach out for more information on the Tetanus Pipeline Report @ Tetanus Preclinical and Discovery Stage Products
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/